Cofrancesco E, Cortellaro M, Corradi A, Ravasi F, Bertocchi F
Institute of Internal Medicine, IRCCS Ospedale Maggiore of Milan, Italy.
Thromb Haemost. 1998 Mar;79(3):509-10.
Measurements of prothrombin fragment 1+2 (F1+2), thrombin antithrombin III complexes (TAT) and D-dimer plasma levels have been proposed as non-invasive screening tests to exclude postoperative deep venous thrombosis (DVT). We investigated the diagnostic efficacy of these coagulation activation markers to rule out postoperative DVT in patients undergoing hip surgery under antithrombotic prophylaxis.
In this substudy of a randomized double-blind thrombosis prophylaxis trial comparing three doses of desirudin (10, 15 or 20 mg b.i.d.) with unfractionated heparin (5000 IU t.i.d.) we used ELISA procedures to measure F1+2, TAT and D-dimer in 159 patients undergoing total hip replacement at baseline (day 0) and on postoperative days 1, 3 and 6. Bilateral venography was performed in all cases 8-11 days after surgery.
For the F1+2 assay sensitivity ranged from 73 to 83% in the three postoperative days investigated, and negative predictive value (NPV) from 68 to 74%. For TAT and D-dimer sensitivity ranged from 71 to 73% and from 71 to 83% and NPV from 61 to 65% and from 61 to 74% respectively.
In terms of sensitivity and NPV F1+2 and D-dimer are equivalent and are superior to TAT. However, their accuracy is too low to rule out the presence of DVT after hip surgery under antithrombotic prophylaxis.
凝血酶原片段1+2(F1+2)、凝血酶-抗凝血酶III复合物(TAT)和D-二聚体血浆水平的检测已被提议作为排除术后深静脉血栓形成(DVT)的非侵入性筛查试验。我们研究了这些凝血激活标志物在接受抗血栓预防的髋关节手术患者中排除术后DVT的诊断效能。
在一项随机双盲血栓预防试验的子研究中,比较三种剂量的地西卢定(10、15或20mg,每日两次)与普通肝素(5000IU,每日三次),我们使用酶联免疫吸附测定法(ELISA)在159例行全髋关节置换术的患者基线(第0天)以及术后第1、3和6天测量F1+2、TAT和D-二聚体。所有病例均在术后8-11天进行双侧静脉造影。
在研究的术后三天中,F1+2检测的敏感性范围为73%至83%,阴性预测值(NPV)为68%至74%。TAT和D-二聚体的敏感性范围分别为71%至73%和71%至83%,NPV分别为61%至65%和61%至74%。
就敏感性和NPV而言,F1+2和D-二聚体相当且优于TAT。然而,它们的准确性太低,无法排除抗血栓预防下髋关节手术后DVT的存在。